Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: A series of 542 patients

International Journal of Surgical Pathology

Volumn 17, Issue 4, 2009, Pages 323-326

  Richter Ehrenstein, Christiane ^a   Müller, Sylvia ^b   Noske, Aurelia ^a   Schneider, Achim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Martin Luther Hospital   (Germany)

Author keywords

Breast cancer; Core biopsy; DCIS; Excision; Her2 neu; Histological grade

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INVASION; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS;

BIOPSY; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 68349147960     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/1066896908327576     Document Type: Article

References (22)

1. Elston CW, Ellis IO Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 ; 19: 403-410.
2. Ellis IO, Galea M., Broughton N., Locker A., Blamey RW, Elston CW Pathological prognostic factors in breast cancer: II. Histological type: relationship with survival in a large study with long-term follow-up. Histopathology. 1992 ; 20: 479-489.
3. Jimenez RE, Wallis T., Tabasczka P., Visscher DW Determination of Her-2/neu status in breast carcinomas: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000 ; 13: 37-45.
4. Liberman L. Percutaneous imaging-guided core breast biopsy: state of the art at the millennium. AJR Am J Roentgenol. 2000 ; 174: 1191-1199.
5. Di Loreto C., Puglisi F., Rimondi G., et al. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer. 1996 ; 32: 1693-1700.
6. Verkooijen HM, Peeters PH, Buskens E., et al. Diagnostic accuracy of large core needle biopsy for non-palpable breast disease: a meta-analysis. Br J Cancer. 2000 ; 82: 1017-1021.
7. Kettritz U., Rotter K., Schreer I. Stereotactic vacuum-assisted breast biopsy in 2874 patients. Cancer. 2004 ; 100: 245-251.
8. Crowe JP Jr, Rim A., Patrick RJ, et al. Does core needle biopsy accurately reflect breast pathology ? Surgery. 2003 ; 134: 523-528.
9. Harris GC, Denley HE, Pinder SE, et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions o invasive breast carcinoma. Am J Surg Pathol. 2003 ; 27: 11-15.
10. Houssami N., Ciatto S., Ellis I., Ambrogetti D. Underestimation of malignancy of breast core-needle biopsy. Cancer. 2007 ; 109: 487-495.
11. Dillon MF, Quinn CM, McDermott EW, O'Doherty A., O'Higgins N., Hill ADK. Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgical practice. J Clin Pathol. 2006 ; 59: 740-743.
12. Jimenez RE, Bongers S., Bouwman D., Segel M., Visscher DW Clinicopathologic significance of ductal carcinoma in situ in breast core needle biopsies with invasive cancer. Am J Surg Pathol. 2000, 24: 123-128.
13. Dahlstrom JE, Sutton S., Jain S. Histological precision of stereotactic core biopsy in diagnosis of malignant and premalignant breast lesions. Histopathology. 1996 ; 28: 537-541.
14. Sharifi S., Peterson MK, Baum JK, Raza S., Schnitt SJ Assessment of pathologic prognostic factors in breast core needle biopsies. Mod Pathol. 1999 ; 12: 941-945. (Pubitemid 29485266)
15. Zidan A., Christie Brown JS, Peston D., Shousha S. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol. 1997 ; 50: 27-29.
16. Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, Jewell WR A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg. 2002 ; 184: 322-324.
17. Barnes DM, Hanby AM Oestrogen and progesterone receptors in breast cancer: past, present and future. Histopathology. 2001 ; 38: 271-274.
18. Buzdar AU Preoperative chemotherapy treatment of breast cancer: a review. Cancer. 2007 ; 110: 2394-2407.
19. Taucher S., Rudas M., Mader RM, et al. Prognostic markers in breast cancer: the reliability of Her2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr. 2004 ; 116: 26-31.
20. Mueller-Holzner E., Fink V., Frede T., Marth C. Immunohistochemical determination of Her2 expression in breast cancer from core biopsy specimen: a reliable predictor of Her2 status of the whole tumor. Breast Cancer Res Treat. 2001 ; 69: 13-19.
21. Chivukula M., Bhargava R., Brufsky A., Surti U., Dabbs D. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection for equivocal (immunohistochemical score 2+) cases. Mod Pathol. 2008 ; 21: 363-368.
22. Bilous M., Dowsett M., Hanna W., et al. Current perspectives on Her2 testing: a review of national testing guidelines. Mod Pathol. 2003 ; 16: 173-182.